FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2332338858> ?p ?o ?g. }

• W2332338858 endingPage "327" @default.
• W2332338858 startingPage "317" @default.
• W2332338858 abstract "Background Here, the baseline and emergent resistance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) versus efavirenz (EFV)/FTC/TDF in HIV-1-infected antiretroviral-naive adults through 144 weeks from the randomized, ongoing, Phase III study GS-US-236-0102 is described. Methods HIV-1 protease (PR) and reverse transcriptase (RT) were sequenced at screening; patients with HIV-1 resistant to EFV, FTC or TDF were excluded. Genotypic/phenotypic analyses were performed at virological failure confirmation and baseline for PR, RT and integrase (IN) for patients with virological failure and for patients with HIV-1 RNA≥400 copies/ml at weeks 48, 96, 144 or early study drug discontinuation. Retrospective, baseline, IN genotyping was conducted for EVG/COBI/FTC/ TDF patients. Results In the EVG/COBI/FTC/TDF group through week 144, HIV-1 from 10 patients (2.9%; 10/348 treated patients) developed primary IN strand transfer inhibitor ( n=9) and/or nucleoside RT inhibitor resistance substitutions ( n=10). The emergence of resistance decreased over time with 8, 2 and 0 patients developing HIV-1 resistance through week 48, post-week 48–96 and post-week 96–144, respectively. Emergent substitutions were E92Q ( n=7), N155H ( n=3), Q148R ( n=1) and T66I ( n=1) in IN, and M184V/I ( n=10) and K65R ( n=4) in RT. All 10 isolates had reduced susceptibility to EVG, FTC or TDF. Virus with EVG phenotypic resistance had cross-resistance to raltegravir. In the EFV/ FTC/TDF group, virus from 14 patients (4.0%; 14/352 treated patients; 4 during weeks 96–144) developed a resistance substitution to EFV ( n=14; K103N: n=13), FTC (M184V/I: n=4) or TDF (K65R: n=3). Conclusions Resistance development to EVG/COBI/FTC/ TDF was infrequent through 144 weeks of therapy and decreased over time, consistent with durable efficacy." @default.
• W2332338858 created "2016-06-24" @default.
• W2332338858 creator A5001632717 @default.
• W2332338858 creator A5008851778 @default.
• W2332338858 creator A5028703048 @default.
• W2332338858 creator A5030772735 @default.
• W2332338858 creator A5033625804 @default.
• W2332338858 creator A5070917710 @default.
• W2332338858 creator A5085171999 @default.
• W2332338858 date "2014-04-01" @default.
• W2332338858 modified "2023-10-02" @default.
• W2332338858 title "Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Efavirenz/Emtricitabine/Tenofovir DF in Antiretroviral-Naive Patients" @default.
• W2332338858 cites W1965104792 @default.
• W2332338858 cites W1976580747 @default.
• W2332338858 cites W1988062692 @default.
• W2332338858 cites W1993363443 @default.
• W2332338858 cites W1996021566 @default.
• W2332338858 cites W2016865365 @default.
• W2332338858 cites W2025952824 @default.
• W2332338858 cites W2053219480 @default.
• W2332338858 cites W2055829400 @default.
• W2332338858 cites W2061817517 @default.
• W2332338858 cites W2068866500 @default.
• W2332338858 cites W2072527802 @default.
• W2332338858 cites W2075531822 @default.
• W2332338858 cites W2094241860 @default.
• W2332338858 cites W2094889034 @default.
• W2332338858 cites W2109046728 @default.
• W2332338858 cites W2122026430 @default.
• W2332338858 cites W2139430929 @default.
• W2332338858 cites W2141287414 @default.
• W2332338858 cites W2145467751 @default.
• W2332338858 cites W2148291080 @default.
• W2332338858 cites W2151050670 @default.
• W2332338858 cites W2154190260 @default.
• W2332338858 cites W2161993838 @default.
• W2332338858 doi "https://doi.org/10.3851/imp2885" @default.
• W2332338858 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25321623" @default.
• W2332338858 hasPublicationYear "2014" @default.
• W2332338858 type Work @default.
• W2332338858 sameAs 2332338858 @default.
• W2332338858 citedByCount "20" @default.
• W2332338858 countsByYear W23323388582015 @default.
• W2332338858 countsByYear W23323388582016 @default.
• W2332338858 countsByYear W23323388582017 @default.
• W2332338858 countsByYear W23323388582018 @default.
• W2332338858 countsByYear W23323388582019 @default.
• W2332338858 countsByYear W23323388582020 @default.
• W2332338858 countsByYear W23323388582021 @default.
• W2332338858 crossrefType "journal-article" @default.
• W2332338858 hasAuthorship W2332338858A5001632717 @default.
• W2332338858 hasAuthorship W2332338858A5008851778 @default.
• W2332338858 hasAuthorship W2332338858A5028703048 @default.
• W2332338858 hasAuthorship W2332338858A5030772735 @default.
• W2332338858 hasAuthorship W2332338858A5033625804 @default.
• W2332338858 hasAuthorship W2332338858A5070917710 @default.
• W2332338858 hasAuthorship W2332338858A5085171999 @default.
• W2332338858 hasConcept C104317684 @default.
• W2332338858 hasConcept C114851261 @default.
• W2332338858 hasConcept C126322002 @default.
• W2332338858 hasConcept C142462285 @default.
• W2332338858 hasConcept C156719811 @default.
• W2332338858 hasConcept C159047783 @default.
• W2332338858 hasConcept C182707283 @default.
• W2332338858 hasConcept C2777068322 @default.
• W2332338858 hasConcept C2778715236 @default.
• W2332338858 hasConcept C2779778239 @default.
• W2332338858 hasConcept C2780404665 @default.
• W2332338858 hasConcept C2780524789 @default.
• W2332338858 hasConcept C2781432083 @default.
• W2332338858 hasConcept C2993143319 @default.
• W2332338858 hasConcept C3013748606 @default.
• W2332338858 hasConcept C54355233 @default.
• W2332338858 hasConcept C67705224 @default.
• W2332338858 hasConcept C71924100 @default.
• W2332338858 hasConcept C86803240 @default.
• W2332338858 hasConcept C90924648 @default.
• W2332338858 hasConceptScore W2332338858C104317684 @default.
• W2332338858 hasConceptScore W2332338858C114851261 @default.
• W2332338858 hasConceptScore W2332338858C126322002 @default.
• W2332338858 hasConceptScore W2332338858C142462285 @default.
• W2332338858 hasConceptScore W2332338858C156719811 @default.
• W2332338858 hasConceptScore W2332338858C159047783 @default.
• W2332338858 hasConceptScore W2332338858C182707283 @default.
• W2332338858 hasConceptScore W2332338858C2777068322 @default.
• W2332338858 hasConceptScore W2332338858C2778715236 @default.
• W2332338858 hasConceptScore W2332338858C2779778239 @default.
• W2332338858 hasConceptScore W2332338858C2780404665 @default.
• W2332338858 hasConceptScore W2332338858C2780524789 @default.
• W2332338858 hasConceptScore W2332338858C2781432083 @default.
• W2332338858 hasConceptScore W2332338858C2993143319 @default.
• W2332338858 hasConceptScore W2332338858C3013748606 @default.
• W2332338858 hasConceptScore W2332338858C54355233 @default.
• W2332338858 hasConceptScore W2332338858C67705224 @default.
• W2332338858 hasConceptScore W2332338858C71924100 @default.
• W2332338858 hasConceptScore W2332338858C86803240 @default.
• W2332338858 hasConceptScore W2332338858C90924648 @default.
• W2332338858 hasIssue "3" @default.

• next